FibroBiologics Inc. Common Stock (FBLG)
Stock · NASDAQ · Health Care
$0.971as of 10/16/2026
Price chart
Active signals
FBLG Signal Track Record
How signals performed across all stocks →What FBLG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 17 | -10.4% | 29% | August 20, 2026 |
| Bollinger Band Breakdown | 13 | -7.4% | 31% | July 27, 2026 |
| Bollinger Band Breakout | 6 | -17.8% | 17% | August 21, 2026 |
| Any 20-session window (baseline) | -14.3% | 23% |
Computed by MarketWall from daily closing prices since November 13, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FBLG
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 15
- Website
- fibrobiologics.com/
Fundamentals
- 1-day range
- $0.96$1.05
- Market cap
- $6.79M
- P/E (trailing)
- —
- P/E (forward)
- -0.31
- EPS (trailing)
- $-5.74
- Dividend yield
- —
- Beta
- 1.83
- Avg. volume
- 209.4K
Forecasts
2 analyst ratings
FibroBiologics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FBLGFibroBiologics Inc. Common Stock$0.971▼ 2.90%Market cap $6.79MP/E —$0.62$9.65
- CVKDCadrenal Therapeutics Inc. Common Stock$1.09▲ 12.37%Market cap $6.67MP/E —$0.8163$14.35
- IMNNImunon Inc. Common Stock$1.02▼ 3.77%Market cap $6.64MP/E —$0.96$5.29
- ALZNAlzamend Neuro Inc. Common Stock$1.3▲ 1.56%Market cap $6.61MP/E —$0.84$2.68
- XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares$1.96▲ 2.62%Market cap $7.05MP/E —$1.6$11.8
- XBIOXenetic Biosciences Inc. Common Stock$1.99▼ 1.00%Market cap $6.53MP/E —$1.87$5.28
- APUSApimeds Pharmaceuticals US Inc. Common Stock$4.04▼ 7.97%Market cap $7.29MP/E —$1.51$403.1
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FBLG FibroBiologics Inc. Common Stock | $6.79M | — | $0.971 | ▼ 2.90% | $0.62$9.65 |
| CVKD Cadrenal Therapeutics Inc. Common Stock | $6.67M | — | $1.09 | ▲ 12.37% | $0.8163$14.35 |
| IMNN Imunon Inc. Common Stock | $6.64M | — | $1.02 | ▼ 3.77% | $0.96$5.29 |
| ALZN Alzamend Neuro Inc. Common Stock | $6.61M | — | $1.3 | ▲ 1.56% | $0.84$2.68 |
| XTLB XTL Biopharmaceuticals Ltd. American Depositary Shares | $7.05M | — | $1.96 | ▲ 2.62% | $1.6$11.8 |
| XBIO Xenetic Biosciences Inc. Common Stock | $6.53M | — | $1.99 | ▼ 1.00% | $1.87$5.28 |
| APUS Apimeds Pharmaceuticals US Inc. Common Stock | $7.29M | — | $4.04 | ▼ 7.97% | $1.51$403.1 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- FibroBiologics Says IP Australia Issues Notice Of Acceptance For Australian Patent Application Titled ‘Cellular Blend For The Regeneration Of Chondrocytes Or Cartilage Type Cells’benzinga · 10/14/2026
- FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the BodyYahoo · 10/7/2026
- EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 InjectionsYahoo · 10/7/2026
- FibroBiologics Files U.S. Patent Application For New Cell-Based Technology Designed To Continuously Produce Peptides Such As GLP-1, GIP and GLP-2 In The BodyBenzinga · 10/7/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 10/2/2026
- FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic ActivityYahoo · 9/29/2026
- FibroBiologics Receives European Patent Titled Methods Of Enhancing Fibroblast Therapeutic ActivityBenzinga · 9/29/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/25/2026
- Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVYahoo · 9/25/2026
Insider Activity
Insider Actions →- Khoja Hamid · September 15, 2026 · Grant298.5K @ $1.68
- Cilento Richard C. Jr. · June 23, 2026 · Grant30.8K
- Niklas Victoria Ninon Olivia · June 23, 2026 · Grant30.8K
- Link Matthew · June 23, 2026 · Grant30.8K
- Robert E. Hoffman · June 23, 2026 · Grant30.8K
- Khoja Hamid · May 4, 2026 · Grant61.6K
- GARCIA RUBEN A · May 4, 2026 · Grant61.6K
- O'HEERON PETE · May 4, 2026 · Grant92.4K
- Davis Jason · May 4, 2026 · Grant61.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 213.1K
- Total value held
- $281.1K
- Institutional holders
- 15
- Unknown67.7K
- Unknown51.8K
- Unknown29.6K
- Unknown24.6K
- Unknown16.4K
- Unknown16.0K
- Unknown5.7K
- Unknown460
- Unknown200
- Unknown186
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
FibroBiologics Secures European Patent for Fibroblast Methods
FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.
FibroBiologics Secures European Patent for Fibroblast Methods. FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.